Hieronim D E, Kanal E, Swanson D P
School of Pharmacy, University of Pittsburgh (UP), PA, USA.
Am J Health Syst Pharm. 1995 Nov 15;52(22):2556-9. doi: 10.1093/ajhp/52.22.2556.
Compliance with an institution's dosage guidelines for gadoteridol was determined, and adverse reactions to gadoteridol and gadopentetate were compared. Departmental policy in March 1993 set the standard dose of gadoteridol at 0.1 mmol/kg. A dose of 0.05 mmol/kg was set for patients with suspected acoustic neurinomas or pituitary microadenomas. Guidelines allowing a high dose of 0.2 or 0.3 mmol/kg were also established for specific indications involving suspected metastatic disease or inadequate contrast enhancement at the standard dose. Data on gadoteridol use were collected concurrently from May 1993 to January 1994 and included the dose, the indication for the dose, and any adverse reactions. Safety data for patients who had received gadopentetate between June 1988 and March 1990 were also collected and reviewed. The subjects in this retrospective analysis represented the same broad population as those involved in the concurrent evaluation of gadoteridol use. The frequency and types of adverse events in the two groups were compared. During the gadoteridol-review period, 8377 patients underwent magnetic resonance imaging studies; 3558 (42.5%) of them received gadoteridol. Of the 3558 doses given, 3375 (94.9%) were 0.1 mmol/kg (the standard dose). Compliance with the guidelines for nonstandard doses was 90% for the 0.3-mmol/kg dose, 74% for the 0.2-mmol/kg dose, and 39% for the 0.05-mmol/kg dose. There were 101 adverse reactions to gadoteridol in 75 (2.1%) of the 3558 recipients. The reactions were mild to moderate and self-limiting. Records for 4892 gadopentetate recipients were analyzed. There were adverse reactions in 62 patients (1.3%). Again, most reactions were mild to moderate. The use of gadoteridol at a medical center generally complied with institutional guidelines. Gadoteridol was well tolerated whether given in standard or high doses. The frequencies and types of adverse reactions to gadoteridol and gadopentetate were similar.
确定了对钆喷酸葡胺的机构剂量指南的遵守情况，并比较了对钆喷酸葡胺和钆双胺的不良反应。1993年3月的部门政策将钆喷酸葡胺的标准剂量设定为0.1 mmol/kg。对于疑似听神经瘤或垂体微腺瘤的患者，设定剂量为0.05 mmol/kg。对于涉及疑似转移性疾病或标准剂量下对比增强不足的特定适应症，还制定了允许使用0.2或0.3 mmol/kg高剂量的指南。1993年5月至1994年1月同时收集了钆喷酸葡胺使用的数据，包括剂量、使用该剂量的适应症以及任何不良反应。还收集并审查了1988年6月至1990年3月期间接受钆双胺的患者的安全数据。这项回顾性分析中的受试者与参与钆喷酸葡胺使用同期评估的受试者代表相同的广泛人群。比较了两组中不良事件的频率和类型。在钆喷酸葡胺审查期间，8377名患者接受了磁共振成像检查；其中3558名（42.5%）接受了钆喷酸葡胺。在给予的3558剂中，3375剂（94.9%）为0.1 mmol/kg（标准剂量）。0.3 mmol/kg剂量对非标准剂量指南的遵守率为90%，0.2 mmol/kg剂量为74%，0.05 mmol/kg剂量为39%。3558名接受者中有75名（2.1%）对钆喷酸葡胺有101次不良反应。这些反应为轻度至中度且为自限性。分析了4892名钆双胺接受者的记录。62名患者（1.3%）出现不良反应。同样，大多数反应为轻度至中度。医疗中心对钆喷酸葡胺的使用总体上符合机构指南。钆喷酸葡胺无论是标准剂量还是高剂量给药，耐受性都良好。钆喷酸葡胺和钆双胺不良反应的频率和类型相似。
